🔗 Share this article

An underground economy for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Investigational Treatment Acquiring Traction Via Social Media

Retatrutide, which remains in clinical trials, is being promoted by social media influencers for its supposed weight-reducing properties. Viewers are urged to contact these profiles privately for source information, while also obtaining discount codes.

Thriving Trade on Messaging Platforms

Additionally, a robust market exists on messaging services, where groups with thousands of participants share “before and after” photos, injection guides and assertions of next-day British shipping. Sellers market the drug there before redirecting buyers to other platforms for purchases.

Understanding Retatrutide

This medication is an investigational injectable developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – GLP-1, GIP and glucagon. Preliminary studies indicate it could assist individuals lose up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being promoted digitally as the next Ozempic.

Medical Experts Voice Concerns

However, physicians and pharmacists have warned that the distribution of what remains an unapproved medication in the United Kingdom is worrisome and could result in users administering products of unknown origin.

Several professionals stated the popularity for the experimental drug could be linked to the increasing cost of approved weight loss treatments such as Mounjaro.

Legal Position and Enforcement

Marketing the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be marketed or supplied for human use under the Human Medicines Regulations 2012.

Some influencers try to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but promotion and distribution can still breach pharmaceutical, advertising, and customer laws, risking penalties, legal action or imprisonment.

Service Reaction and Material Removal

According to the social media company, the platform has removed violative content and banned associated keywords and query recommendations. The organization stated it was committed to maintaining the platform safe and investing in enhancing enforcement strategies.

Digital Marketplace Activities

Investigations also discovered groups with up to nine thousand members selling retatrutide using the platform's built-in search feature, which operates like a online catalog. Entering “retatrutide” immediately brings up channels with numerous of members, populated with photos of slimming results, positive testimonials and detailed instructions for mixing or administering at residence.

After moments of joining one group, a vendor shared WhatsApp details, where the majority of purchases take place. The vendor provided an guidebook and promised delivery within 48 hours. When asked whether the substance was genuine, one seller said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about body mass, health issues or past usage.

Product Information and Costs

Within these groups, posts show black plastic parcels with Royal Mail labels, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with sterile water, or ready-to-use injectors typically sold at 160 pounds for 20 milligrams. When questioned how long a injector should be used, sellers give contradictory answers varying between a several days to “depends on your body”.

Platform Oversight and Security Measures

A spokesperson for Telegram said it actively monitored harmful content on its service including content that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are injecting materials they cannot confirm. Even if the research behind retatrutide is valid, these digital products may not contain what they claim,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the surge in interest to current cost increases for authorized slimming medications such as Mounjaro. “With costs rising, patients are turning to social media. But counterfeit treatments are extremely dangerous. You cannot know what’s inside or whether the conditions they were produced in was sterile,” she said.

Her team has already encountered patients harmed by self-injection from unverified sources. “We understand the disappointment, but buying from messaging apps or WhatsApp is gambling with your health,” said the doctor. “These materials could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from the pharmaceutical company stated the substance was in phase 3 clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for personal consumption,” they said, noting that any item “misleadingly claiming itself as a company experimental product not yet approved … may expose patients to potentially significant medical dangers”.